Northview Acquisition Corp (NVAC) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Mar 31 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Northview Acquisition Corp  (NASDAQ: NVAC)


Northview Acquisition's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Northview Acquisition's ROI in the second quarter of 2026?
Due to the stockholders deficit and subsequent negative measured investments, it was not possible to calculate Northview Acquisition Corp's return on investment (ROI) in its second quarter of 2026

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter
Y / Y Investment Change TTM - - - - -
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions -16 -28 -13 -116 -119
Return On Investment (TTM) - - - - -
NVAC's Overall Ranking # # # # #
Seq. Investment Change TTM - - - - -
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -27 -21 -19 -10 -10

NVAC Company Profile >> Back to NVAC Roi Comparisons >> See Annual NVAC Return On Investment



Return On Investment NVAC's Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Investment Statistics
High Average Low
0 %
0 %
0 %
 







Financial Statements
Northview Acquisition's II. Quarter Investments $ -16 Millions NVAC's Balance sheet
Northview Acquisition's II. Quarter Income $ -9 Millions Quarterly NVAC's Income Statement
NVAC's Income by Division See NVAC's Income by Division


NVAC Annual Return On Investment (Sep 30 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions -19 -4 -100 194 193
Y / Y Investment Growth - - - 0.44 % -
Net Income in Millions -22 -9 3 7 0
Y / Y Net Income Growth - - -53.97 % 2285.8 % -
Annual Return On Investment - - - 3.7 % 0.16 %


Annual Roi Comment
Despite deterioration in net income, company improved ROI to in the fiscal year 2025, company improved ROI to 0.16 % compare to previous year.

Definition and Formula of Return on Investment

Other ROI Ratios
Medical Equipment & Supplies Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
NVAC's Roi Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for NVAC's Competitors
Subscribers only: Roi for Northview Acquisition's Suppliers
Subscribers only: Return On Investment for NVAC's Customers

Other Ratios
NVAC's Roa NVAC's Inventory Turnover Ratio NVAC's Growth Rates NVAC's Dividend Statistics
NVAC's Profitability Ratios NVAC's Asset Turnover Ratio NVAC's Dividend Growth
NVAC's Roe NVAC's Valuation Ratios NVAC's Financial Strength Ratios NVAC's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI
Sanuwave Health Inc   167.92 %
Vor Biopharma Inc   162.71 %
Capforce Inc   161.42 %
Kyntra Bio Inc   157.74 %
Silexion Therapeutics Corp  127.60 %
Quince Therapeutics Inc   112.49 %
Pulmatrix Inc   108.83 %
Interpace Biosciences Inc   100.71 %
Rigel Pharmaceuticals Inc  89.00 %
Oncotelic Therapeutics Inc   87.35 %
Arbutus Biopharma Corp  85.89 %
Actinium Pharmaceuticals Inc  84.38 %
Exelixis Inc   82.05 %
Lensar Inc   75.31 %
Ironwood Pharmaceuticals inc   70.54 %
Oramed Pharmaceuticals Inc  68.90 %
Indivior Pharmaceuticals Inc   68.79 %
Rallybio Corporation  68.28 %
Fortress Biotech Inc   68.27 %
Earth Science Tech Inc   64.38 %
Meiragtx Holdings Plc  55.83 %
Elite Pharmaceuticals Inc   53.48 %
Idexx Laboratories Inc  51.80 %
Aurinia Pharmaceuticals Inc   50.35 %
Qhslab Inc   48.94 %
Q32 Bio Inc   47.43 %
Vaxart Inc   46.17 %
Liquidia Corporation  42.09 %
Tg Therapeutics Inc   39.26 %
Medpace Holdings Inc   35.54 %

Date modified: 2026-09-26T07:41:22+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.